Project Grant R21AG102431
- The National Institute on Aging awarded Jackson Laboratory $486,750 on June 15, 2026, under the Aging Research program (CFDA 93.866) to engineer a human glial-neuronal microphysiological system for studying myelination and axonal-synaptic pathology in Alzheimer's disease. The project develops a tri-culture platform integrating neurons, astrocytes, and oligodendrocytes on a microfluidic system to enable axonal maturation, myelination, and synaptic connectivity under physiological conditions. This...
- The National Institute on Aging awarded Beth Israel Deaconess Medical Center, Inc. $518,555 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop spatially validated human lymphoid follicles-on-chip for modeling inflammaging and age-related immune dysfunction. The recipient will establish a lymphoid follicle organ-on-chip platform that recapitulates key hallmarks of human lymphoid function, including germinal center formation, AID expression, and antiviral antibody...
- The National Institute on Aging awarded $648,930 to the Regents of the University of California, doing business as University of California, Berkeley, on August 15, 2026, under the Aging Research program (CFDA 93.866) to develop human stem cell-based microphysiological systems for aging research. The recipient will create a novel human aging-on-a-chip platform integrating fat and liver tissues derived from human induced pluripotent stem cells (hiPSCs) and microfluidics using serum from young...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded The Johns Hopkins University $427,625 for Project Grant R21AG102518 on September 1, 2026, under the Aging Research program (CFDA 93.866). The recipient will develop a human three-dimensional neuromuscular microphysiological system to model skeletal muscle aging ex vivo. The platform integrates primary human muscle stem cells from young (20–30 years) and aged (60–75 years) donors, induced pluripotent...
- The National Institute on Aging awarded Duke University $664,591 under the Aging Research program (CFDA 93.866) on September 1, 2026, to identify bioactive metabolites produced by beneficial gut bacteria and determine their mechanisms of action on host aging. The research applies a high-throughput, mass spectrometry-based pipeline to construct strain-specific metabolic profiles of human anaerobic gut bacteria, with particular focus on bifidobacteria. The project aims to identify...
- The National Institute on Aging awarded Albany Medical College $246,000 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate inter-organelle dynamics during aging in eukaryotic cells. The work will characterize spatial contexts of inter-organelle communication using C. elegans as a model system to identify organellar signatures that develop during aging and proteostasis decline, establishing a platform to understand how aging impacts organelle interactions and...
- The National Institute on Aging awarded the University of Texas Medical Branch at Galveston $444,125 on August 15, 2026, under the Aging Research program (CFDA 93.866) to investigate whether youthful gut microbiomes slow or reverse physiological aging in mice through fecal microbiota transplantation (FMT). The project, designated R21AG103130, will test two hypotheses across two research aims over a performance period ending July 31, 2028. Aim 1 will determine whether autologous FMT using...
- The National Institute on Aging awarded Yale University $544,318 under the Aging Research program (CFDA 93.866) on June 1, 2026, to conduct research on immunometabolic regulation of inflammaging by nerve-associated macrophages (NAMs). The project investigates how nerve-associated macrophages—a subset of macrophages residing on sympathetic nerve fibers—regulate the sympathetic nervous system and innate immune response to control chronic inflammation associated with aging. The research addresses...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded Jackson Laboratory $486,750 under the Aging Research program (CFDA 93.866) for a two-year project beginning September 1, 2025, and concluding August 31, 2027. This Project Grant funds research investigating the impact of age-related clonal hematopoiesis (CH)—a condition in which blood-forming stem cells accumulate somatic mutations that provide selective growth advantages—on Alzheimer's disease (AD) pathology onset...
- The National Institute on Aging awarded Brigham & Womens Hospital Inc. $135,540 under Project Grant K99AG097920 on July 1, 2026, to investigate microbial aging dynamics in cognitive health through a multi-omics approach. The award falls under the Aging Research program (CFDA 93.866), which supports biomedical, social, and behavioral research directed toward understanding the aging process and Alzheimer's disease and related dementias. The research integrates multi-omics analysis to examine...
The National Institute on Aging awarded The Jackson Laboratory $506,000 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop an age-stratified human gut-on-chip model that integrates organoid-derived young and old colon epithelia with patient-derived microbiomes within a dynamically perfused, oxygen-controlled microphysiological environment. The recipient will establish the first such platform capable of sustaining obligate anaerobes and examining how aging-related changes in host epithelium and microbiome composition individually and in concert shape barrier function and inflammatory signaling. The project benchmarks molecular and functional hallmarks of colon epithelial aging—including barrier loss, lineage imbalance, mitochondrial dysfunction, and senescence-associated secretory phenotype—by comparing young and old organoid-derived tissue across controlled apical-basal oxygen gradients. The work addresses the mechanistic connection between microbiome aging and epithelial decline, with implications for understanding age-associated infection risk, frailty, cognitive decline, metabolic disorders, and cardiovascular disease. Performance occurs in Farmington, Connecticut, with a period of performance ending August 31, 2028. The assistance type is Project Grant.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $506.0k | 9/1/26 |